FertilityX
FertilityX28About
What does FertilityX do?
FertilityX is developing AI-powered solutions to address male fertility challenges. Their technology aims to enhance diagnostic precision and treatment success rates, assisting couples on their journey to biological parenthood.
What is FertilityX's revenue?
StartupHub estimates FertilityX's annual revenue at $177K (range $104K to $433K, 67% confidence), based on comparable companies in the sector.
Where is FertilityX headquartered?
FertilityX is headquartered in Tel Aviv, Israel.
When was FertilityX founded?
FertilityX was founded in 2023.
What industry does FertilityX operate in?
FertilityX operates in Healthcare, Fertility, HealthTech, MedTech, AI-Driven Drug Discovery, Genomics.
How many employees does FertilityX have?
FertilityX has approximately 1 people on record.
What is FertilityX's current status?
FertilityX's current operating status is: Inactive.
Lymesignal is an AI-assisted platform that transforms publicly available Lyme disease discussions into organized, searchable community knowledge.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
A science-based digital program and app designed to help adults manage ADHD symptoms and build coping skills.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaƱa. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 11 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.